A family of pleiotropically acting micrornas in cancer progression, mir-200: Potential cancer therapeutic targets

Current Pharmaceutical Design

Volumn 20, Issue 11, 2014, Pages 1896-1903

  Zhang, Hai Feng ^a,b   Xu, Li Yan ^a   Li, En Min ^a  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Angiogenesis; Cancer stem ells; Cancer therapeutics; Epithelial to mesenchymal transition; MiR 200 family; Tumor metastasis

Indexed keywords

BMI1 PROTEIN; MICRORNA 200; VASCULOTROPIN A; MICRORNA; MIRN200 MICRORNA, HUMAN;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CANCER STEM CELL; CANCER THERAPY; CELL INVASION; DEREGULATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR INVASION; ANIMAL; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; NEOPLASMS; PATHOLOGY;

ANIMALS; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84903710564     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990519     Document Type: Review

References (135)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
2. Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 2010; 11: 252-63.
3. Forman JJ, Coller HA. The code within the code: microRNAs target coding regions. Cell Cycle 2010; 9: 1533-41.
4. Reczko M, Maragkakis M, Alexiou P, et al. Functional microRNA targets in protein coding sequences. Bioinformatics 2012; 28: 771-6.
5. Lee I, Ajay SS, Yook JI, et al. New class of microRNA targets containing simultaneous 5'-UTR and 3'-UTR interaction sites. Genome Res 2009; 19: 1175-83.
6. Ørom UA, Nielsen FC, Lund AH. MicroRNA-10a Binds the 5_UTR of Ribosomal Protein mRNAs and Enhances Their Translation. Mol Cell 2008; 30: 460-71.
7. Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. Dev Cell 2006; 11: 441-50.
8. Leung AK, Sharp PA. microRNAs: a safeguard against turmoil? Cell 2007; 130: 581-5.
9. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell 2005; 122: 6-7.
10. Sassen S, Miska EA, Caldas C. MicroRNA: implications for cancer. Virchows Arch 2008; 452: 1-10.
11. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012; 4: 143-59.
12. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9: 775-89.
13. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269.
14. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2005; 120: 635-47.
15. Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133: 647-58.
16. Darido C, Georgy SR, Wilanowski T, et al. Targeting of the tumor suppressor GRHL3 by a miR-21-dependent proto-oncogenic network results in PTEN loss and tumorigenesis. Cancer Cell 2011; 20: 635-48.
17. Ma L, Young J, Prabhala H, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12: 247-56.
18. Chang TC, Yu D, Lee YS, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008; 40: 43-50.
19. Dews M, Homayouni A, Yu D, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006; 38: 1060-5.
20. O'Donnell KA, Wentzel EA, Zeller KI, et al. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005; 435: 839-43.
21. He L, He XY, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447: 1130-34.
22. Chang CJ, Chao CH, Xia W, et al. p53 regulates epithelialmesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 2011; 13: 317-23.
23. Kim T, Veronese A, Pichiorri F, et al. p53 regulates epithelialmesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med 2011; 208: 875-83.
24. Esteller M. Epigenetics in Cancer. N Engl J Med 2008; 358: 1148-59.
25. Gosden RG, Feinberg AP. Genetics and epigenetics--nature's penand- pencil set. N Engl J Med 2007; 356: 731-3.
26. Ganesan A, Nolan L, Crabb SJ, et al. Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery. Curr Cancer Drug Targets 2009; 9: 963-81.
27. Zheng H, Wu H. Enhancement on the predictive power of the prediction model for human genomic DNA methylation. International Conference on Bioinformatics and Computational Biology (BIOCOMP), 2011.
28. Christman JK. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002; 21: 5483-95.
29. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 2008; 123: 8-13.
30. Yeh CC, Deng YT, Sha DY, et al. Suberoylanilide hydroxamic acid sensitizes human oral cancer cells to TRAIL-induced apoptosis through increase DR5 expression. Mol Cancer Ther 2009; 8: 2718-25.
31. Butler LM, Liapis V, Bouralexis S, et al. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. Int J Cancer 2006; 119: 944-54.
32. Elmén J, Lindow M, Schütz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008; 452: 896-9.
33. Ma L, Reinhardt F, Pan E, et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 2010; 28: 341-7.
34. Burk U, Schubert J, Wellner U, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008; 9: 582-9.
35. Bracken CP, Gregory PA, Kolesnikoff N, et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res 2008; 68: 7846-54.
36. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593-601.
37. Korpal M, Lee ES, Hu G, et al. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283: 14910-4.
38. Park SM, Gaur AB, Lengyel E, et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the Ecadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22: 894-907.
39. Shimono Y, Zabala M, Cho RW, et al. Downregulation of miRNA- 200c links breast cancer stem cells with normal stem cells. Cell 2009; 138: 592-603.
40. Wellner U, Schubert J, Burk UC, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009; 11: 1487-95.
41. Iliopoulos D, Lindahl-Allen M, Polytarchou C, et al. Loss of miR- 200 inhibition of SUZ12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell 2010; 39: 761-72.
42. Iliopoulos D, Polytarchou C, Hatziapostolou M, et al. MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Sci Signal 2009; 2
43. Chan YC, Khanna S, Roy S, et al. miR-200b targets ETS1 and is down-regulated by hypoxia to induce angiogenic response of endothelial cells. J Biol Chem 2011; 286: 2047-56
44. Choi YC, Yoon S, Jeong Y, et al. Regulation of Vascular Endothelial Growth Factor Signaling by miR-200b. Mol Cells 2011; 32: 77-82.
45. Roybal JD, Zang Y, Ahn YH, et al. miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting FLT1/VEGFR1. Mol Cancer Res 2011; 9: 25-35.
46. Chan YC, Roy S, Khanna S, et al. Downregulation of endothelial microRNA-200b supports cutaneous wound angiogenesis by desilencing GATA binding protein 2 and vascular endothelial growth factor receptor 2. Arterioscler Thromb Vasc Biol 2012; 32: 1372-82.
47. McArthur K, Feng B, Wu Y, et al. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes 2011; 60: 1314-23.
48. Adam L, Zhong M, Choi W, et al. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 2009; 15: 5060-72.
49. Cochrane DR, Spoelstra NS, Howe EN, et al. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubuletargeting chemotherapeutic agents. Mol Cancer Ther 2009; 8: 1055-66.
50. Li Y, VandenBoom TG 2nd, Kong D, et al. Up-regulation of miR- 200 and let-7 by natural agents leads to the reversal of epithelial-tomesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009; 69: 6704-12.
51. Cochrane DR, Howe EN, Spoelstra NS, et al. Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers. J Oncol 2010; 2010: 821717.
52. Tryndyak VP, Beland FA, Pogribny IP. E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer 2010; 126: 2575-83.
53. van Jaarsveld MT, Helleman J, Berns EM, et al. MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol 2010; 42: 1282-90.
54. Rui W, Bing F, Hai-Zhu S, et al. Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1). J Cell Mol Med 2010; 14: 206-14.
55. Wu XM, Shao XQ, Meng XX, et al. Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin- resistant gastric cancer cells. Acta Pharmacol Sin 2011; 32: 259-69.
56. Feng B, Wang R, Song HZ, et al. MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3. Cancer 2012; 118: 3365-76.
57. Korpal M, Ell BJ, Buffa FM, et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med 2011; 17: 1101-8.
58. Dykxhoorn DM, Wu Y, Xie H, et al. miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One 2009; 4: e7181.
59. Wicha MS, Liu S, Dontu G. Cancer Stem Cells: An Old Idea-A Paradigm Shift. Cancer Res 2006; 66: 1883-90.
60. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-11.
61. Molofsky AV, He S, Bydon M, et al. Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev 2005; 19: 1432-7.
62. Park IK, Qian D, Kiel M, et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003; 423: 302-5.
63. Pietersen AM, Evers B, Prasad AA, et al. Bmi1 regulates stem cells and proliferation and differentiation of committed cells in mammary epithelium. Curr Biol 2008; 18: 1094-9.
64. Boyer LA, Plath K, Zeitlinger J, et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 2006; 441: 349-353.
65. Lee TI, Jenner RG, Boyer LA, et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 2006; 125: 301-313.
66. Squazzo SL, O'Geen H, Komashko VM, et al. SUZ12 binds to silenced regions of the genome in a cell-type-specific manner. Genome Res 2006; 6: 890-900.
67. Zhong X, Li Y, Peng F, et al. Identification of tumorigenic retinal stem-like cells in human solid retinoblastomas. Int J Cancer 2007; 121: 2125-2131.
68. Bracken AP, and Helin K. Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer 2009; 9: 773-784.
69. Hoenerhoff MJ, Chu I, Barkan D, et al. BMI1 cooperates with HRAS to induce an aggressive breast cancer phenotype with brain metastases. Oncogene 2009; 28: 3022-3032.
70. Thiery JP, Sleeman JP. Complex networks orchestrate epithelialmesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7: 131-142.
71. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial- mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005; 17: 548-558.
72. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003; 15: 740-746.
73. Brabletz T, Jung A, Spaderna S, et al. Migrating cancer stem cells - an integrated concept of malignant tumor progression. Nat Rev Cancer 2005; 5: 744-9.
74. Gotzmann J, Huber H, Thallinger C, et al. Hepatocytes convert to a fibroblastoid phenotype through the cooperation of TGF-beta1 and Ha-Ras: Steps towards invasiveness. J Cell Sci 2002; 115: 1189-1202.
75. Baumgart E, Cohen MS, Silva NB, et al. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. Clin Cancer Res 2007; 13: 1685-94.
76. Brabletz S, Brabletz T. The ZEB/miR-200 feedback loop-a motor of cellular plasticity in development and cancer? EMBO Rep 2010; 11: 670-7.
77. Liu YN, Yin JJ, Abou-Kheir W, et al. MiR-1 and miR-200 inhibit EMT via SLUG-dependent and tumorigenesis via SLUGindependent mechanisms. Oncogene 2012; 32: 296-306.
78. Sun L, Yao Y, Liu B, et al. MiR-200b and miR-15b regulate chemotherapy- induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene 2012; 31: 432-45.
79. Eades G, Yao Y, Yang M, et al. miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J Biol Chem 2011; 286: 25992-6002.
80. Olson P, Lu J, Zhang H, et al. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev 2009; 23: 2152-65.
81. Gibbons DL, Lin W, Creighton CJ, et al. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR- 200 family expression. Genes Dev 2009; 23: 2140-51.
82. Vallejo DM, Caparros E, Dominguez M. Targeting Notch signalling by the conserved miR-8/200 microRNA family in development and cancer cells. EMBO J 2011; 30: 756-69.
83. Brabletz S, Bajdak K, Meidhof S, et al. The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J 2011; 30: 770-82.
84. Yang Y, Ahn YH, Gibbons DL, et al. The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200- dependent pathway in mice. J Clin Invest 2011; 121: 1373-85.
85. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265e73.
86. Yates CC, Shepard CR, Stolz DB, et al. Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin. Br J Cancer 2007; 96: 1246e52.
87. Kowalski PJ, Rubin MA, Kleer CG. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res 2003; 5: R217e22.
88. Hur K, Toiyama Y, Takahashi M, et al. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut Published Online First: 10 July 2012. Available from: http://gut.bmj.com/content/early/2012/07/09/gutjnl-2011-301846.
89. Gravgaard KH, Lyng MB, Laenkholm AV, et al. The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer. Breast Cancer Res Treat 2012; 134: 207-17.
90. Sabbah M, Emami S, Redeuilh G, et al. Molecular signature and therapeutic perspective of the epithelialto-mesenchymal transitions in epithelial cancers. Drug Resist Updat 2008; 11: 123-51.
91. Fuchs BC, Fujii T, Dorfman JD, et al. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res 2008; 68: 2391-9.
92. Leskelä S, Leandro-García LJ, Mendiola M, et al. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer 2010; 18: 85-95.
93. Pogribny IP, Filkowski JN, Tryndyak VP, et al. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer 2010; 127: 1785-94.
94. Kovalchuk O, Filkowski J, Meservy J, et al. Involvement of microRNA- 451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 2008; 7: 2152-9.
95. Ali S, Ahmad A, Banerjee S, et al. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 2010; 70: 3606-17.
96. Bao B, Ali S, Kong D, et al. Anti-tumor activity of a novel compound- CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One 2011; 6: e17850.
97. Soubani O, Ali AS, Logna F, et al. Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1- MMP in pancreatic cancer. Carcinogenesis 2012; 33: 1563-71.
98. Liao CH, Sang S, Ho CT, et al. Garcinol modulates tyrosine phosphorylation of FAK and subsequently induces apoptosis through down-regulation of Src, ERK, and Akt survival signaling in human colon cancer cells. J Cell Biochem 2005; 96: 155-69.
99. Ahmad A, Wang Z, Ali R, et al. Apoptosis-inducing effect of garcinol is mediated by NF-kappaB signaling in breast cancer cells. J Cell Biochem 2010; 109: 1134-41.
100. Prasad S, Ravindran J, Sung B, et al. Garcinol potentiates TRAILinduced apoptosis through modulation of death receptors and antiapoptotic proteins. Mol Cancer Ther 2010; 9: 856-68.
101. Ahmad A, Sarkar SH, Bitar B, et al. Garcinol regulates EMT and Wnt signaling pathways in vitro and in vivo leading to anticancer activity against breast cancer cells. Mol Cancer Ther 2012; 11: 2193-201.
102. Schliekelman MJ, Gibbons DL, Faca VM, et al. Targets of the tumor suppressor miR-200 in regulation of the epithelialmesenchymal transition in cancer. Cancer Res 2011; 71: 7670-82.
103. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007; 4: 721-6.
104. Akinc A, Zumbuehl A, Goldberg M, et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 2008; 26: 561-9.
105. Arima Y, Hayashi H, Sasaki M, et al. Induction of ZEB proteins by inactivation of RB protein is key determinant of mesenchymal phenotype of breast cancer. J Biol Chem 2012; 287: 7896-906.
106. Gregory PA, Bracken CP, Smith E, et al. An autocrine TGFbeta/ ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell 2011; 22: 1686-98.
107. Ahmad A, Aboukameel A, Kong D, et al. Phosphoglucose isomerase/autocrine motility factor mediates epithelialmesenchymal transition regulated by miR-200 in breast cancer cells. Cancer Res 2011; 71: 3400-9.
108. Howe EN, Cochrane DR, Richer JK. Targets of miR-200c mediate suppression of cell motility and anoikis resistance. Breast Cancer Res 2011; 13: R45.
109. Uhlmann S, Zhang JD, Schwäger A, et al. miR-200bc/429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer. Oncogene 2010; 29: 4297-306.
110. Sossey-Alaoui K, Bialkowska K, Plow EF. The miR200 family of microRNAs regulates WAVE3-dependent cancer cell invasion. J Biol Chem 2009; 284: 33019-29.
111. Jurmeister S, Baumann M, Balwierz A, et al. MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F. Mol Cell Biol 2012; 32: 633-51.
112. Tellez CS, Juri DE, Do K, et al. EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res 2011; 71: 3087-97.
113. Wang Z, Zhao Y, Smith E, et al. Reversal and prevention of arsenic- induced human bronchial epithelial cell malignant transformation by microRNA-200b. Toxicol Sci 2011; 121: 110-22.
114. Hung CS, Liu HH, Liu JJ, et al. MicroRNA-200a and -200b Mediated Hepatocellular Carcinoma Cell Migration Through the Epithelial to Mesenchymal Transition Markers. Ann Surg Oncol 2012 Aug 7. Available from: http://link.springer.com/article/10.1245%2Fs10434-012-2482-4.
115. Zhang Z, Liu ZB, Ren WM, et al. The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells. Int J Mol Med 2012; 30: 856-62.
116. Braun J, Hoang-Vu C, Dralle H, et al. Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. Oncogene 2010; 29: 4237-44.
117. Ono H, Imoto I, Kozaki K, et al. SIX1 promotes epithelialmesenchymal transition in colorectal cancer through ZEB1 activation. Oncogene 2012; 314923-34.
118. Kong D, Banerjee S, Ahmad A, et al. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One 2010; 5: e12445.
119. Kong D, Li Y, Wang Z, et al. miR-200 regulates PDGF-Dmediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 2009; 27: 1712-21.
120. Kurashige J, Kamohara H, Watanabe M, et al. MicroRNA-200b Regulates Cell Proliferation, Invasion, and Migration by Directly Targeting ZEB2 in Gastric Carcinoma. Ann Surg Oncol 2012; 19 Suppl 3: 656-64.
121. Shinozaki A, Sakatani T, Ushiku T, et al. Downregulation of microRNA- 200 in EBV-associated gastric carcinoma. Cancer Res 2010; 70: 4719-27.
122. Du Y, Xu Y, Ding L, et al. Down-regulation of miR-141 in gastric cancer and its involvement in cell growth. J Gastroenterol 2009; 44: 556-61.
123. Su J, Zhang A, Shi Z, et al. MicroRNA-200a suppresses the Wnt/_- catenin signaling pathway by interacting with _-catenin. Int J Oncol 2012; 40: 1162-70.
124. Cai J, Liu X, Cheng J, et al. MicroRNA-200 is commonly repressed in conjunctival MALT lymphoma, and targets cyclin E2. Graefes Arch Clin Exp Ophthalmol 2012; 250: 523-31.
125. Mateescu B, Batista L, Cardon M, et al. miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med 2011; 17: 1627-35.
126. Chen J, Wang L, Matyunina LV, et al. Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells. Gynecol Oncol 2011; 121: 200-5.
127. Bendoraite A, Knouf EC, Garg KS, et al. Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol 2010; 116: 117-25.
128. Wiklund ED, Bramsen JB, Hulf T, et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 2011; 128: 1327-34.
129. Xia H, Ng SS, Jiang S, et al. miR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion. Biochem Biophys Res Commun 2010; 391: 535-41.
130. Lo WL, Yu CC, Chiou GY, et al. MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and neck squamous cell carcinoma stem cells. J Pathol 2011; 223: 482-95.
131. Saydam O, Shen Y, Würdinger T, et al. Downregulated microRNA- 200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Mol Cell Biol 2009; 29: 5923-40.
132. Hamano R, Miyata H, Yamasaki M, et al. Overexpression of miR- 200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin Cancer Res 2011; 17: 3029-38.
133. Elson-Schwab I, Lorentzen A, Marshall CJ. MicroRNA-200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion. PLoS One 2010; 5
134. Kent OA, Mullendore M, Wentzel EA, et al. A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol Ther 2009; 8: 2013-24.
135. Mees ST, Mardin WA, Wendel C, et al. EP300--a miRNAregulated metastasis suppressor gene in ductal adenocarcinomas of the pancreas. Int J Cancer 2010; 126: 114-24.